FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma
Author:
Publisher
Elsevier BV
Subject
Drug Discovery,Pharmacology
Reference45 articles.
1. Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer;Castellanos;J. Thorac. Oncol.,2017
2. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death;Chen;J. Exp. Clin. Cancer Res.,2019
3. Long non-coding RNA CASC9 promotes gefitinib resistance in NSCLC by epigenetic repression of DUSP1;Chen;Cell Death Dis.,2020
4. A phase 1/2 study of lazertinib 240 mg in patients with advanced EGFR t790m-positive NSCLC after previous EGFR tyrosine kinase inhibitors;Cho;J. Thorac. Oncol.,2022
5. The EZH2-PHACTR2-AS1-ribosome Axis induces genomic instability and promotes growth and metastasis in breast cancer;Chu;Cancer Res.,2020
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Strategies for enhancing non-small cell lung cancer treatment: Integrating Chinese herbal medicines with epidermal growth factor receptor-tyrosine kinase inhibitors therapy;European Journal of Pharmacology;2024-10
2. Overexpression of EZH2 is associated with clinicopathological parameters and poor prognosis in gliomas;2024-04-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3